TrialBlood advances2024

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Stephan Stilgenbauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.